The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...

Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...

After hours: March 12 at 6:24:06 PM EDT Loading Chart for NBIX ...

Stay in the loop with the latest aviation news & aircraft deals. It is our mission to be the go-to leaders in the aviation industry. GlobalAir.com is your partner in connecting you with relevant ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.